Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval
Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies is under clinical development by Bristol-Myers Squibb and...